Tests calderasib with pembrolizumab in lung cancer with KRAS G12C mutation
Tests calderasib plus pembrolizumab as first treatment in adults with KRAS G12C lung cancer.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Bupyeong-gu, Daegu, Hwasun, Incheon, Junggu, Seoul, Suwon, and Yangsan, South KoreaSee the 12 sitesAlso in 29 other countries, 237 sites
- Trial code
- NCT06345729
- EU 2023-507776-42-00
- JRCT2031240213
- U1111-1296-8093
- Registry title
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 348 people, planned
- Started
- 24 May 2024
- Expected to end
- 18 Feb 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Calderasib
- Placebo
- Pembrolizumab
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and a PD-L1 score of 50% or more. It tests calderasib plus pembrolizumab as first treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer, newly diagnosed Stage IIIB/IIIC that cannot be treated with surgery or with chemotherapy/radiation meant to remove all of the disease, or Stage IV.
- Earlier treatment
- No earlier systemic anticancer treatment for locally advanced or metastatic lung cancer. Side effects from earlier treatments must have recovered to Grade 1 or baseline.
- Biomarker or test result
- KRAS G12C mutation and PD-L1 tumor proportion score of 50% or more, tested on a tumor sample.
Main reasons for not taking part
- Small cell lung cancer, including mixed tumors with small cell parts
- Active brain or spinal fluid cancer spread (CNS metastases or carcinomatous meningitis)
- Active autoimmune disease treated in the past 2 years, or active inflammatory bowel disease
- Past or current pneumonitis or interstitial lung disease that needed steroids
- Earlier donor tissue or solid organ transplant
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
- Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research
- If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to < Grade 1 or baseline
- If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
- If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
- If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable
Who cannot take part
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
- Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC
- Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
- Has received radiotherapy to non-central nervous system (CNS) disease within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis
- Has not fully recovered from any effects of major surgical procedure
- Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible
- Has known history of, or active, neurologic paraneoplastic syndrome
- Has an active infection requiring systemic therapy, with exceptions
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has history of allogenic tissue/solid organ transplant
- Has known active CNS metastases and/or carcinomatous meningitis
Other criteria
- The main inclusion and exclusion criteria include but are not limited to the following:
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- What was the PD-L1 result of your tumour test?
- Has your cancer spread to the brain?
- Has your cancer spread to the lining around the brain or spinal cord?
Where in South Korea
Also in 29 other countries, 237 sites
- The Catholic University of Korea, Incheon St. Mary's Hospital (Site 3606)Bupyeong-gu, South KoreaContact: Study CoordinatorTaking people
- Keimyung University Dongsan Hospital (Site 3611)Daegu, South KoreaContact: Study CoordinatorTaking people
- Yeungnam University Hospital (Site 3607)Daegu, South KoreaContact: Study CoordinatorTaking people
- Chonnam National University Hwasun Hospital-Pulmonology (Site 3604)Hwasun, South KoreaContact: Toll Free NumberNo longer taking part
- Inha University Hospital (Site 3610)Incheon, South KoreaContact: Study CoordinatorTaking people
- Chungnam national university hospital (Site 3602)Junggu, South KoreaContact: Study CoordinatorTaking people
- Korea University Anam Hospital (Site 3609)Seoul, South KoreaContact: Study CoordinatorTaking people
- Korea University Guro Hospital (Site 3601)Seoul, South KoreaContact: Study CoordinatorTaking people
- Kyung Hee University Hospital (Site 3605)Seoul, South KoreaContact: Study CoordinatorTaking people
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital (Site 3608)Seoul, South KoreaContact: Study CoordinatorTaking people
- The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology (Site 3600)Suwon, South KoreaContact: Study CoordinatorTaking people
- Pusan National University Yangsan Hospital-Lung Cancer Clinic (Site 3603)Yangsan, South KoreaContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis:
Read full original descriptionShow less
Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
The 2 groups in the trial
- Calderasib with PembrolizumabTreatment being tested
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (q3w) for up to 35 cycles and calderasib by oral tablets until discontinuation criterion is met.
Treatment: Calderasib and Pembrolizumab
- Placebo with PembrolizumabExisting treatment, for comparison
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (q3w) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met.
Treatment: Placebo and Pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)
- Plain-language title
- Tests calderasib with pembrolizumab in lung cancer with KRAS G12C mutationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06345729, who can take part
- Record updated
- 12 November 2026